Detalles de la búsqueda
1.
Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study).
Cardiovasc Diabetol
; 19(1): 93, 2020 06 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-32560724
2.
New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence.
Cardiovasc Diabetol
; 18(1): 80, 2019 06 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-31208414
3.
Abrogation of postprandial triglyceridemia with dual PPAR α/γ agonist in type 2 diabetes mellitus: a randomized, placebo-controlled study.
Acta Diabetol
; 57(7): 809-818, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-32030508
4.
Effect of Food on the Pharmacokinetics of Saroglitazar Magnesium, a Novel Dual PPARαγ Agonist, in Healthy Adult Subjects.
Clin Drug Investig
; 38(1): 57-65, 2018 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-29022212
5.
Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers.
Clin Pharmacokinet
; 57(1): 87-102, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28508936
Resultados
1 -
5
de 5
1
Próxima >
>>